Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party.
Shumilov, Evgenii Ngoya, Maud Berning, Philipp Devillier, Raynier Forcade, Edouard Schroeder, Thomas Kroschinsky, Frank Stelljes, Matthias Valkova, Veronika Kinsella, Francesca
Shumilov, Evgenii
Ngoya, Maud
Berning, Philipp
Devillier, Raynier
Forcade, Edouard
Schroeder, Thomas
Kroschinsky, Frank
Stelljes, Matthias
Valkova, Veronika
Kinsella, Francesca
Abstract
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-SCT) is an established treatment for peripheral T-cell lymphoma (PTCL), particularly for patients with relapsed/refractory (r/r) disease. We aimed to retrieve novel information on the role of histology, disease status prior to transplantation, and donor choice for patients with PTCL not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic lymphoma kinase (ALK)-negative ALCL. We compared imaging by computed tomography (CT) or positron emission tomography (PET) for defining disease status prior to allo-SCT.
METHODS: Eligible were adult patients with PTCL-NOS, AITL, and ALK-negative ALCL undergoing allo-SCT between 2010 and 2022 and reported to EBMT.
RESULTS: 1958 patients underwent allo-SCT. Of patients with known number of prior lines of therapies (nā=ā1310), 301 (23%), 431 (32.9%) and 578 (44.1%) patients received allo-SCT after one (1L), two (2L) or three or more therapy lines (3Lā+), respective. Three-year GvHD-free, relapse-free survival (GRFS), progression-free survival (PFS) and overall survival (OS) were 35.8%, 50.9% and 56.8%, respectively. Three-year relapse incidence (RI) and non-relapse mortality were 25.1% and 24.1%, respectively. In multivariate analysis, histology other than AITL, no complete response (CR) at transplantation, having a haploidentical donor and higher age at allo-SCT resulted in significantly lower PFS and/or OS. Prior autologous SCT had no impact on the results of allo-SCT and major outcomes did not significantly change when the analyses were restricted to the patients with PET-based response at allo-SCT. Patients allografted in partial response (PR) or SD/PD still achieved long-term survival with a 3-year PFS/OS of 46%/53.7% and 39.6%/43.6%, respectively.
CONCLUSION: Allo-SCT is a valid treatment option in relapsed/refractory PTCL where targeted therapies still play a limited role. Patients with AITL survived significantly better than patients with PTCL NOS or ALK-negative ALCL following a significantly lower RI, also when comparing CR/complete metabolic response (CMR) and PR patients separately. Higher age and non-CR at allo-SCT are associated with worse outcomes.
MIDER Authors
Kinsella, Francesca
Citations
publications.citations-section.null.title:
Altmetric:
Date
2026-02-21
Type
Article
Subject
Collections
An error occurred retrieving the object's statistics
Citation
Shumilov E, Ngoya M, Berning P, Devillier R, Forcade E, Schroeder T, Kroschinsky F, Stelljes M, Valkova V, Kinsella F, Chevallier P, Olesen G, Mohty M, de Fontbrune FS, Wagner-Drouet E, Zeiser R, Herling M, Franke GN, LĆ³pez-Corral L, Ayuk F, Lenz G, Wulf G, Sureda A, Laurence A, Dreger P, Bazarbachi A, Schmitz N. Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party. J Hematol Oncol. 2026 Feb 21;19(1):17. doi: 10.1186/s13045-026-01783-w.
Journal / Source Title
Journal of Hematology & Oncology
DOI
10.1186/s13045-026-01783-w
PMID
41723532
Publisher
Biomed Central
Publisherās URL
https://jhoonline.biomedcentral.com/